AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9105569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8255447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (3 grams oral daily add-on therapy)
Number of subjects: 168
Study 8255447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily add-on therapy)
Number of subjects: 168
Study 3516908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermodress
Number of subjects: 10
Study 3516908 — intervention group
Group type: COMPARATOR
Intervention: Furacin gauze
Number of subjects: 10
Study 31659608 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFEChildren preventive intervention applied during first grade
Number of subjects: 424
Study 31659608 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 424
Study 28745475 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyPump (high‐repetition, low to moderate load RT)
Number of subjects: 18
Study 28745475 — intervention group
Group type: COMPARATOR
Intervention: Heavy load RT (linear periodization with 3‐6, 8‐10 and 13‐15 repetitions, 2‐4 series)
Number of subjects: 18
Study 27100716 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anesthesiologist administration of propofol (Group A)
Number of subjects: 277
Study 27100716 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist-administered sedation (Group B)
Number of subjects: 277
Study 24177711 — intervention group
Group type: EXPERIMENTAL
Intervention: Halliwick‐Therapy (n = 14)
Number of subjects: 30
Study 24177711 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 30
Study 22244014 — intervention group
Group type: EXPERIMENTAL
Intervention: Orafti® Synergy1 (β2-1 fructans) 8 g/d
Number of subjects: 43
Study 22244014 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 43
Study 20924148 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐number long‐interval (HL) arm flex/extend exercise
Number of subjects: 8
Study 20924148 — intervention group
Group type: COMPARATOR
Intervention: Low‐number short‐interval (LS) arm flex/extend exercise
Number of subjects: 8
Study 18980521 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 0.5% AZM (group 2)
Number of subjects: 80
Study 18980521 — intervention group
Group type: COMPARATOR
Intervention: SRP only (group 1)
Number of subjects: 80
Study 18980521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 16204748 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab with an initial heparin bolus of 50 U/kg (n = 128)
Number of subjects: 254
Study 16204748 — intervention group
Group type: COMPARATOR
Intervention: Placebo with an initial heparin bolus of 70 U/kg (n = 126)
Number of subjects: 254
Study 16204748 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab group
Number of subjects: 254
Study 16204748 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 254
Study 12414410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration homogenized castor oil eye drops (2% castor oil and 5% polyoxyethylene castor oil)
Number of subjects: 20
Study 12414410 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 20
Study 9498724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (i.v. bolus of 0.26 mg/kg followed by an infusion of 0.65 mg/kg per hour)
Number of subjects: 23
Study 9498724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg, PO
Number of subjects: 23
Study 7883925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pontoon spica group (treated with a few days in traction followed by 90‐90 pins‐in‐plastic spica)
Number of subjects: 91
Study 7883925 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (treated with 3 weeks in traction followed by spica)
Number of subjects: 91
Study 2294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary calcium intake (dairy products) by an average of 610 mg/day for 3 years
Number of subjects: 37
Study 2294135 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and weight-matched women)
Number of subjects: 37
Study 118329 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of chemotherapy for an additional three years
Number of subjects: 220
Study 118329 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of therapy
Number of subjects: 220
Study 118329 — intervention group
Group type: EXPERIMENTAL
Intervention: Total patient group
Number of subjects: 220
Study 118329 — intervention group
Group type: EXPERIMENTAL
Intervention: Males in randomized group
Number of subjects: 220
Study 30496350 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg tribendimidine
Number of subjects: 130
Study 30496350 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tribendimidine
Number of subjects: 130
Study 30496350 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tribendimidine
Number of subjects: 130
Study 30496350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 29079039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoate 2g/day
Number of subjects: 53
Study 29079039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins E 364mg/day + C 1000mg/day
Number of subjects: 53
Study 29079039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ethyl-EPA and vitamins E+C
Number of subjects: 53
Study 26854288 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-abdominal removal of the placenta
Number of subjects: 210
Study 26854288 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal removal of the placenta
Number of subjects: 210
Study 24991933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT) at 3 L/min
Number of subjects: 23
Study 24991933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (2 × 250 mg tablets)
Number of subjects: 23
Study 24991933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 23
Study 24991933 — intervention group
Group type: COMPARATOR
Intervention: All treatments (NOT, acetazolamide, placebo)
Number of subjects: 23
Study 23173988 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth seat group
Number of subjects: 0
Study 23173988 — intervention group
Group type: COMPARATOR
Intervention: Control group (any other position for vaginal birth)
Number of subjects: 0
Study 21058210 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week resistance training programme
Number of subjects: 12
Study 21058210 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 17362708 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom counseling provided during the screening visit
Number of subjects: 314
Study 17362708 — intervention group
Group type: COMPARATOR
Intervention: Prior to counseling
Number of subjects: 314
Study 15602643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ash Split catheter (AS)
Number of subjects: 69
Study 15602643 — intervention group
Group type: COMPARATOR
Intervention: PermCath catheter (PC)
Number of subjects: 69
Study 12540325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated chart review and prompt to physicians
Number of subjects: 997
Study 12540325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 997
Study 12540325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 997
Study 9822508 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 8.4% sodium bicarbonate (1:10)
Number of subjects: 24
Study 9822508 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine lumbar epidural anesthesia
Number of subjects: 24
Study 8132440 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserine (30-60 mg/day)
Number of subjects: 40
Study 8132440 — intervention group
Group type: EXPERIMENTAL
Intervention: fluvoxamine (50-100 mg/day)
Number of subjects: 40
Study 8132440 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 2679331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.25 mg
Number of subjects: 35
Study 2679331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.75 mg
Number of subjects: 35
Study 2679331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 1.5 mg
Number of subjects: 35
Study 2679331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 2.5 mg
Number of subjects: 35
Study 2679331 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg diamorphine)
Number of subjects: 35
Study 1177541 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training by usual teachers who received special educational program
Number of subjects: 100
Study 535777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 600 micrograms
Number of subjects: 50
Study 535777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 900 micrograms
Number of subjects: 50
Study 535777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 100 micrograms
Number of subjects: 50
Study 535777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 200 micrograms
Number of subjects: 50
Study 535777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride 300 micrograms
Number of subjects: 50
Study 535777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocryptine 2.5 mg
Number of subjects: 50
Study 535777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31008634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 592
Study 31008634 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss
Number of subjects: 592
Study 31008634 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 592
Study 31008634 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 592
Study 30134883 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotape (KT)
Number of subjects: 39
Study 30134883 — intervention group
Group type: COMPARATOR
Intervention: Sham tape (ST)
Number of subjects: 39
Study 30134883 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 39
Study 26777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 380
Study 27128840 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab derived from Sp2/0 cell line
Number of subjects: 0
Study 27128840 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab derived from CHO cell line
Number of subjects: 0
Study 22434736 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly newsletters
Number of subjects: 53
Study 22434736 — intervention group
Group type: COMPARATOR
Intervention: Monthly group classes and telephone behavioural sessions
Number of subjects: 53
Study 19067471 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (10-40 mg) with amlodipine 5 mg for 8 weeks
Number of subjects: 755
Study 19067471 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptitration of olmesartan medoxomil/amlodipine to 20/5 mg, 40/5 mg, or 40/10 mg
Number of subjects: 755
Study 19067471 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus amlodipine 5 mg for 8 weeks
Number of subjects: 755
Study 15288987 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses with or without patches
Number of subjects: 177
Study 15288987 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasses alone
Number of subjects: 177
Study 15288987 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment for 1 year
Number of subjects: 177
Study 12213846 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO (hypothyroid)
Number of subjects: 162
Study 12213846 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO + rhTSH (hypothyroid + recombinant human TSH)
Number of subjects: 162
Study 9620508 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Mz) alone
Number of subjects: 100
Study 9620508 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Pf) alone
Number of subjects: 100
Study 9620508 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Mz) in combination with Propofol (Pf)
Number of subjects: 100
Study 9620508 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 7650148 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 21
Study 7650148 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 21
Study 7650148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 2655365 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% mepivacaine with epinephrine 5 micrograms/ml (3 ml at each pin site)
Number of subjects: 20
Study 2655365 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 814825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyperalimentation
Number of subjects: 34
Study 814825 — intervention group
Group type: COMPARATOR
Intervention: Control (no hyperalimentation)
Number of subjects: 34
Study 31797548 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized healing abutment
Number of subjects: 36
Study 31797548 — intervention group
Group type: COMPARATOR
Intervention: Standard healing abutment
Number of subjects: 36
Study 30477858 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble cinnamon extract
Number of subjects: 103
Study 30477858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 27579926 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (6 interventions over 6 months)
Number of subjects: 210
Study 27579926 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring (control group)
Number of subjects: 210
Study 24474147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydrocortisone
Number of subjects: 10
Study 24474147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22699287 — intervention group
Group type: EXPERIMENTAL
Intervention: gevokizumab
Number of subjects: 98
Study 22699287 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study 20575921 — intervention group
Group type: EXPERIMENTAL
Intervention: Open staff-assisted glove donning
Number of subjects: 40
Study 20575921 — intervention group
Group type: COMPARATOR
Intervention: Closed staff-assisted glove donning
Number of subjects: 40
Study 18487887 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Taiji and Qigong (TQ) practice for 5 months
Number of subjects: 50
Study 18487887 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 18487887 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Taiji and Qigong (TQ) practice
Number of subjects: 50
Study 15853863 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR (days 1-3, 150 mg/day; days 4-49, 150 mg twice daily)
Number of subjects: 690
Study 15853863 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 690
Study 12861232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min/day, 5 days/week) for 16 months
Number of subjects: 131
Study 12861232 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal physical activity)
Number of subjects: 131
Study 11292113 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Ems salt
Number of subjects: 43
Study 11292113 — intervention group
Group type: COMPARATOR
Intervention: Inhaled isotonic saline
Number of subjects: 43
Study 11292113 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Ems salt (cough group)
Number of subjects: 43
Study 8619450 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 400-mg doses of artesunate followed by two doses of mefloquine (750 mg immediately and 500 mg 12 hr later)
Number of subjects: 111
Study 8619450 — intervention group
Group type: EXPERIMENTAL
Intervention: Four 200-mg doses of artesunate given 12 hr apart followed by a mefloquine regimen similar to Group I
Number of subjects: 111
Study 8619450 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (four 200-mg doses of artesunate followed by mefloquine)
Number of subjects: 111
Study 8619450 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (two 400-mg doses of artesunate followed by mefloquine)
Number of subjects: 111
Study 1313591 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 26
Study 1313591 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 26
Study 1313591 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26
Study 3891239 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide ointment applied twice daily for two weeks
Number of subjects: 34
Study 3891239 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment applied twice daily for two weeks
Number of subjects: 34
Study 30031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity based group therapy (1 hour duration, once a week for 4 weeks)
Number of subjects: 34
Study 30031995 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity based group therapy
Number of subjects: 34
Study 30031995 — intervention group
Group type: COMPARATOR
Intervention: Control group (assessed using the State‐Trait Anxiety Inventory (STAI‐S) once at recruitment and again 4 weeks later)
Number of subjects: 34
Study 27419804 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluence, high repetition rate 810-nm diode laser in SHR mode
Number of subjects: 92
Study 27419804 — intervention group
Group type: COMPARATOR
Intervention: High fluence, low repetition rate diode laser in HR mode
Number of subjects: 92
Study 23390066 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session reality therapy drug treatment program
Number of subjects: 48
Study 23390066 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 22743149 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day for 16 weeks
Number of subjects: 288
Study 22743149 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 288
Study 20483194 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia using liposomal lidocaine
Number of subjects: 0
Study 20483194 — intervention group
Group type: COMPARATOR
Intervention: Vapocoolant spray
Number of subjects: 0
Study 20483194 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered tactile stimulation
Number of subjects: 0
Study 20483194 — intervention group
Group type: COMPARATOR
Intervention: Self-directed distraction (reading a magazine)
Number of subjects: 0
Study 18304971 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, learner‐centred educational methods in large and small group settings
Number of subjects: 192
Study 18304971 — intervention group
Group type: COMPARATOR
Intervention: Standard programme of continuing medical education (CME)
Number of subjects: 192
Study 16115125 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSET transfected cell lines
Number of subjects: 37
Study 16115125 — intervention group
Group type: EXPERIMENTAL
Intervention: t(4;14)+ MM patients
Number of subjects: 37
Study 12433720 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I levels in cases
Number of subjects: 456
Study 12433720 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-3 levels in cases
Number of subjects: 456
Study 12433720 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I levels in heaviest smokers (2nd to 4th quartiles)
Number of subjects: 456
Study 12433720 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-3 levels in highest quartile
Number of subjects: 456
Study 12433720 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I levels in younger subjects
Number of subjects: 456
Study 12433720 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking or recent cessation effects on IGF-I levels
Number of subjects: 456
Study 10468689 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐ASA 100 mg/day
Number of subjects: 59
Study 10468689 — intervention group
Group type: COMPARATOR
Intervention: Plain ASA 100 mg/day
Number of subjects: 59
Study 10468689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8707779 — intervention group
Group type: EXPERIMENTAL
Intervention: Wee Wheezers asthma education program
Number of subjects: 76
Study 1836097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous nitroglycerin infusion
Number of subjects: 310
Study 7201725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent (1, 3, 4, 12F) polysaccharide pneumococcal vaccine
Number of subjects: 68
Study 7201725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent (14, 18C, 19F, 23F) vaccine
Number of subjects: 68
Study 7201725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentadecavalent vaccine (1, 3, 4, 6A, 7F, 8, 9N, 11A, 12F, 14, 15F, 18C, 19F, 23F)
Number of subjects: 68
Study 7201725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30815861 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Number of subjects: 101
Study 30815861 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 101
Study 31310993 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit Plus® intervention
Number of subjects: 24
Study 31310993 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 28622623 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib 200mg
Number of subjects: 39
Study 28622623 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib 100mg and 200mg
Number of subjects: 39
Study 28622623 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 39
Study 27362239 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IUI (n = 290)
Number of subjects: 580
Study 27362239 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI (n = 290)
Number of subjects: 580
Study 27362239 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Single and Double IUI
Number of subjects: 580
Study 25176414 — intervention group
Group type: EXPERIMENTAL
Intervention: Box trainer training (1 hour per week for 4 weeks)
Number of subjects: 22